A binary self-amplifying expression platform that makes the body its own biologics factory — without lipid nanoparticles, without the cold chain, without the limits of first-generation vectors.
By a simple intramuscular injection, the construct enters cells and self-amplifies — directing sustained production of the encoded protein or antibody. Carrier-optional and non-viral.
Any protein or antibody, optimized with Jennerator AI.
Naked IM injection. Room-temperature stable.
Constructs amplify inside the cell.
Therapeutic levels for months.
Durable genetic medicines have faced a hidden ceiling — and it's almost never the genetic payload. It's the delivery system. Lipid nanoparticles introduce PEGylated lipids the immune system learns to clear, blunting every dose after the first. Viral vectors introduce a protein capsid that triggers neutralizing antibodies, often making a second dose impossible. The Gemini platform carries neither.
Our non-viral, self-amplifying DNA is engineered to deliver months of protein expression without a lipid nanoparticle and without a viral capsid. By removing the two components that provoke carrier immunity, the platform is designed to be redosed when treatment calls for it — not just once, but as needed.
| mRNA-LNP | AAV gene therapy | Eyam (saDNA) | |
|---|---|---|---|
| Duration of expression | Hours | Years | 6+ months (preclinical) |
| Redosing | Limited by anti-PEG response | Limited by anti-capsid immunity | Designed to redose as needed |
| Delivery carrier | PEGylated lipid nanoparticle | Viral capsid | Non-viral, non-nanoparticle |
Why it matters. Most durable-expression technologies force a trade-off between how long a dose lasts and whether you can give another one. By engineering durability into the construct rather than the carrier, Eyam is designed to offer both — sustained expression and the flexibility to redose — from a single, non-viral platform.
Jefferies et al., Nature Communications (2025) — open access. Read the paper →
| Gemini (Eyam) | mRNA-LNP | DNA + EP | AAV | |
|---|---|---|---|---|
| Carrier | None — naked IM | LNP required | EP device | Viral capsid |
| Duration | 6+ months | Days | Weeks | Years (no redose) |
| Payload | ~16–20 kb / 5 ORFs | ~4 kb | 1–2 ORFs | ~4.7 kb |
| Cold chain | Ambient stable | Ultra-cold | Ambient | Cold |
| Redosing | Designed to redose | Limited (anti-PEG) | Yes | Limited (anti-capsid) |
| Manufacturing | Simple plasmid; 60–80% lower COGS | Complex | Moderate | Complex viral |
Jennerator AI. Where Gemini is the expression engine, Jennerator is the design accelerator. Our AI-driven immunoinformatics engine predicts epitopes, optimizes HLA/MHC binding, and tunes payloads for expression and durability — so every Gemini construct starts with the best possible cargo.
Produced with conventional plasmid DNA manufacturing at standard CDMOs — no microfluidic LNP formulation, no ultra-cold logistics. 60–80% lower cost of goods, lyophilizable, ambient-shipped, field-reconstituted.